Market Place
Sourcing Support
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
Top drugs and pharmaceutical companies of 2019 by revenues
Acquisitions and spin-offs dominated headlines in 2019 and the tone was set very early with Bristol-
Analyzing over US$ 90 billion of Medicare Prescription Drug (Part D) Spending in 2016
This week, PharmaCompass
reviews the recently released data on prescription drugs paid for under th
Amsterdam to host EMA; China pulls Skype out of app stores
This week in Phispers, we tell you how Amsterdam became EU’s choice for hosting the EMA. As Bi
Dead fish in Hyderabad puts pharma majors under scrutiny; False data uncovered in AstraZeneca’s US$ 4 billion buy
This week, Phispers has news from across the world. While China is trying to speed up approval of dr
Drug costs and prescription trends in the United States: Analyzing Medicare’s $121 billion spend
In less than three weeks, Donald Trump will assume office as the
President of the United States. He
How little-known Lannett may soon become a billion-dollar generic company?
In August, when Fortune magazine
published its latest ranking of the fastest-growing companies in t
Merck vs Merck: A ‘Mercky’ tale
It doesn’t help that the company, which calls
itself Merck in the United States isn’t al
